Product launches ExoELISA-Step kit and Human Capture Beads recently launched, signaling active expansion in exosome research tools and isolation capabilities. This presents a sales opportunity to position complementary reagents, kits, and related diagnostics solutions to customers adopting these new offerings.

Diagnostic growth Expansion into exosome detection and isolation aligns with increasing interest in exosome-based diagnostics and liquid biopsy workflows. Target customers in clinical research and diagnostic development may be receptive to integrated workflows that combine the new ExoELISA-Step kit with compatible reagents and instrumentation.

Flow cytometry StarBright fluorescent dyes added to the IVD reagent range indicate a push into flow cytometry applications. This creates cross-sell opportunities for existing customers using flow cytometry platforms, reagents, and analytics software, as well as partnerships with instrument vendors.

SMB growth potential With a small-to-mid-size employee base and revenue in the low single-digit millions, Immunostep is likely agile and price-conscious. This suggests favorable conditions for bundled offerings, tiered pricing, and quick-onboarding pilot programs to drive early adoption.

Global enablement The combination of online presence, diverse tech stack, and recent product launches indicates a go-to-market strategy focused on digital channels and collaborations. Sales efforts could emphasize international outreach, distributor partnerships, and educational content to accelerate adoption among researchers and diagnostic labs.